SIRT6 Benefits: What Studies Report

SIRT6 is a NAD⁺-dependent enzyme in the sirtuin family. It is a protein encoded by the genome, not an injectable compound, and most of what is known about it comes from genetically modified cells, knockout and overexpression mouse models, and pharmacological activators tested in animals. This page organises what published studies measured and reported by outcome domain. Nothing here is a claim that SIRT6 activity produces a benefit in people.

This page is for educational purposes only and is not medical advice; consult a licensed physician about any health question or before making decisions related to any substance or intervention.

What Kind of Evidence Exists

The literature on SIRT6 is dominated by mechanistic biology. Studies have typically used one of four designs: comparative cell biology across species, mouse knockout or overexpression models, pharmacological activation in rodents, or observational analyses of tissue samples. Large randomised human trials with SIRT6 activity as an intervention were not found in the verified literature reviewed for this page; where human data appear, they are usually tissue-level or biomarker analyses, as in work on sirtuins and microRNAs after acute myocardial infarction (PMID 41462250).

DNA Repair and Longevity Biology

The most frequently cited SIRT6 finding concerns DNA double-strand break repair. A 2019 study in Cell compared cells from multiple mammalian species and reported that SIRT6 was responsible for more efficient DNA double-strand break repair in long-lived species, with the researchers attributing interspecies differences in repair efficiency to SIRT6 activity rather than to other repair machinery (PMID 31002797). That study was comparative cell biology; it did not test whether increasing SIRT6 activity extends lifespan in humans, and it should not be read as a human longevity outcome.

Related work has examined how SIRT6 intersects with metabolic ageing. A 2025 study in PNAS reported that Sirt6 prevented the age-related decline of hydrogen sulfide through control of one-carbon metabolism in mice, linking the enzyme to a gasotransmitter pathway associated with ageing phenotypes (PMID 41218122). Again, the model was murine, and the measured endpoints were biochemical rather than clinical.

What this does and does not support

• Reported: a mechanistic association between SIRT6 activity and repair efficiency across species (PMID 31002797).
• Reported: an age-related biochemical pathway controlled by Sirt6 in mice (PMID 41218122).
• Not reported in these papers: human lifespan, healthspan scores, or any outcome from supplementation.

Mitochondrial Quality and Cellular Housekeeping

A 2025 review in Molecular and Cellular Biochemistry described sirtuins as key gatekeepers of mitochondrial quality through mitophagy, summarising how members of the family, including SIRT6, have been linked in laboratory work to the clearance of damaged mitochondria (PMID 40705152). Reviews of this kind aggregate preclinical mechanisms; they do not themselves generate outcome data, and the review format means findings were drawn from heterogeneous cell and animal systems.

Adjacent to this, a 2022 analysis in Circulation reanalysed mechanisms proposed for the cardiorenal effects of SGLT2 inhibitors and reaffirmed a nutrient deprivation signalling and autophagy hypothesis, a framework in which sirtuin signalling is one of the nutrient-sensing elements discussed (PMID 36315602). That paper was a mechanistic reanalysis of drug effects, not a study of SIRT6 as an intervention.

Cardiovascular and Vascular Ageing

A 2016 review in the Canadian Journal of Cardiology examined sirtuins, cell senescence and vascular ageing, describing pathways through which sirtuin activity has been connected in preclinical work to endothelial senescence and arterial ageing (PMID 26948035). The review characterised mechanisms rather than treatment effects.

More recently, a 2025 paper in Cardiovascular Diabetology investigated sirtuins and regulatory microRNAs as epigenetic determinants of empagliflozin-mediated recovery after acute myocardial infarction, placing sirtuin expression within a biomarker framework for post-infarction recovery (PMID 41462250). The reported relationship was between a drug's effects and sirtuin-related epigenetic markers; SIRT6 was not administered, and the study does not establish that raising SIRT6 improves cardiac outcomes.

Brain, Cognition and Mood: Animal Models Only

Two rodent studies illustrate how SIRT6 has been examined in neuroscience. A 2023 study in Neural Regeneration Research reported that overexpression of Sirt6 ameliorated sleep deprivation-induced cognitive impairment in mice by modulating glutamatergic neuron function (PMID 37282476). The manipulation was genetic overexpression in an induced-deficit model, not a supplement given to healthy animals.

A 2025 study in Journal of Advanced Research reported that activation of Sirt6 by icariside II alleviated depressive behaviours in mice with post-stroke depression, with the researchers describing modulation of the microbiota-gut-brain axis as the proposed mechanism (PMID 40037430). Behavioural endpoints in mice do not translate directly to human mood disorders, and no human trial of this approach appears in the verified set.

Inflammation and NAD Metabolism

SIRT6 depends on NAD⁺, so NAD biology is frequently discussed alongside it. A 2018 study in Gut reported that NAD metabolism fuelled human and mouse intestinal inflammation, examining NAD-dependent pathways in inflamed intestinal tissue (PMID 28877980). The direction of that finding is worth noting carefully: the researchers described NAD metabolism as contributing to inflammation in that setting, which runs against a simple assumption that more NAD-dependent signalling is uniformly favourable.

Cancer: Opposing Findings, Not a Benefit Claim

SIRT6 is sometimes described online as protective against cancer. The published picture is explicitly двусторонняя. A 2021 review in Cancers titled its analysis around the two-faced role of SIRT6 in cancer, describing contexts in which SIRT6 behaved as a tumour suppressor and others in which it supported tumour biology (PMID 33800266). Any page presenting SIRT6 as straightforwardly anti-cancer is not representing that review accurately.

Tumour-microenvironment work adds further context. A 2024 study in Science Translational Medicine reported that TSPAN8-positive myofibroblastic cancer-associated fibroblasts promoted chemoresistance in patients with breast cancer, illustrating how stromal and epigenetic programmes can work against treatment response (PMID 38569015). Separately, a 2025 study in Advanced Science reported that methionine metabolism dictated PCSK9 expression and the antitumour potency of PD-1 blockade in microsatellite-stable colorectal cancer, another example of metabolic signalling shaping tumour response in directions that depend on context (PMID 40125618).

Claims With Weak or Absent Evidence

Several benefits attached to SIRT6 in popular writing are not supported in the verified literature reviewed here:

• Human lifespan extension. The comparative DNA-repair work described species-level correlations, not human outcomes (PMID 31002797).
• Fat loss or body-composition change. No human trial in this citation set measured weight, fat mass or metabolic endpoints as an outcome of SIRT6 activation.
• Skin or hair effects. Not addressed in any of the papers cited on this page.
• A defined dose of a SIRT6 activator in humans. The activator evidence here is a mouse study of icariside II in post-stroke depression (PMID 40037430); no human dosing regimen is established by it.
• Uniform cancer protection. Explicitly contradicted by the review describing opposing roles (PMID 33800266).

Safety and Tolerability: What Studies Report

Because SIRT6 is an endogenous enzyme rather than an administered product in most of this literature, adverse-event tables of the kind found in drug trials are largely absent. The relevant cautionary signals are biological rather than clinical. The Cancers review described contexts in which SIRT6 supported rather than suppressed tumour biology, which the authors framed as a reason to treat activation strategies cautiously (PMID 33800266). The Gut study reported that NAD metabolism fuelled intestinal inflammation in human and mouse tissue, another instance where a pathway often framed positively showed an adverse direction in a specific disease setting (PMID 28877980). No study in this set reported a human safety profile for a SIRT6-targeting intervention.

How to Read SIRT6 Headlines

1. Check the organism. Mouse overexpression findings, such as the sleep-deprivation cognition study, describe genetic manipulation rather than a treatment people received (PMID 37282476).
2. Check whether SIRT6 was the intervention or the marker. In the post-infarction work, sirtuins were measured as epigenetic determinants alongside a drug, not given as a therapy (PMID 41462250).
3. Check direction by tissue. Mitophagy reviews describe sirtuins favourably in mitochondrial quality control (PMID 40705152), while other settings report unfavourable directions (PMID 28877980).
4. Treat reviews as maps, not evidence. The vascular ageing review summarised mechanisms rather than testing them (PMID 26948035).

Taken together, the papers cited across this page describe SIRT6 as a context-dependent regulator studied mainly in cells and rodents, with repair efficiency across species (PMID 31002797) and ageing-related metabolic control in mice (PMID 41218122) among the most frequently cited findings, and with cancer biology described as two-sided (PMID 33800266).

References

• SIRT6 Is Responsible for More Efficient DNA Double-Strand Break Repair in Long-Lived Species (Cell, 2019)
• Sirt6 prevents the age-related decline of H(2)S through the control of one-carbon metabolism (PNAS, 2025)
• Sirtuins in mitophagy: key gatekeepers of mitochondrial quality (Molecular and Cellular Biochemistry, 2025)
• Critical Reanalysis of the Mechanisms Underlying the Cardiorenal Benefits of SGLT2 Inhibitors and Reaffirmation of the Nutrient Deprivation Signaling/Autophagy Hypothesis (Circulation, 2022)
• Sirtuins, Cell Senescence, and Vascular Aging (The Canadian Journal of Cardiology, 2016)
• Sirtuins and regulatory miRNAs as epigenetic determinants of empagliflozin-mediated recovery after acute myocardial infarction (Cardiovascular Diabetology, 2025)
• Overexpression of Sirt6 ameliorates sleep deprivation induced-cognitive impairment by modulating glutamatergic neuron function (Neural Regeneration Research, 2023)
• Activation of Sirt6 by icariside II alleviates depressive behaviors in mice with poststroke depression by modulating microbiota-gut-brain axis (Journal of Advanced Research, 2025)
• NAD metabolism fuels human and mouse intestinal inflammation (Gut, 2018)
• The Two-Faced Role of SIRT6 in Cancer (Cancers, 2021)
• TSPAN8(+) myofibroblastic cancer-associated fibroblasts promote chemoresistance in patients with breast cancer (Science Translational Medicine, 2024)
• Methionine Metabolism Dictates PCSK9 Expression and Antitumor Potency of PD-1 Blockade in MSS Colorectal Cancer (Advanced Science, 2025)